Skip to main content
  • Login
  • Contact
  • Subscribe
  • Advertise With Us

Search form

Home

The Pilot News

Plymouth weather info

  • Home
    • Forms
  • News
    • Local News
    • The Leader of Starke County
    • Culver Citizen
    • Business News
  • Sports
  • Obituaries
  • Classifieds
    • Place an Ad
    • Classified Display Ads
  • Entertainment
    • Calendar
    • Best Of
    • Special Sections
    • Talking About...
    • Games
  • Photos
  • Videos
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Arrowhead Pharma (NQ: ARWR)
18.88 USD  +0.26 (+1.40%)
Official Closing Price  /  Updated: 6:56 PM EDT, Mar 18, 2019  /  Add to My Watchlist      
View: Quote
Overview
Detailed Quote
Charting
Historical Prices
 News
All News
Press Releases
Related Stories
Blogs
 Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,464,300
Open 18.88
Bid (Size) 18.46 (3)
Ask (Size) 18.97 (3)
Prev. Close 18.62
Today's Range 18.53 - 19.41
52wk Range 6.307 - 22.39
Shares Outstanding 87,577,188
Dividend Yield N/A
Performance
YTD
+43.90%
+43.90%
1 Month
+4.14%
+4.14%
3 Month
+35.24%
+35.24%
6 Month
+3.68%
+3.68%
1 Year
+163.32%
+163.32%
Top News
More News
Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Today 7:30 EDT
Arrowhead Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease and plans to initiate in the second quarter of 2019 Read More
from Business Wire News Releases
Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
March 11, 2019
Arrowhead dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based investigational medicine to treat hypertriglyceridemia Read More
from Business Wire News Releases
More News
Read More
Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences
March 01, 2019
from Business Wire News Releases
Report: Exploring Fundamental Drivers Behind TD Ameritrade Holding, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Nucor, Portland General Electric, and TrueBlue — New Horizons, Emerging Trends, a
January 31, 2019
from GlobeNewswire News Releases
Analysts Anticipate PWC Will Reach $105
March 11, 2019
category ETFs
from ETF Channel
Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results
February 07, 2019
from Business Wire News Releases
Arrowhead Pharma Has Returned 33.1% Since SmarTrend Recommendation (ARWR)
March 14, 2019
from Comtex SmarTrend® News Briefs
Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results
January 24, 2019
from Business Wire News Releases
27.1% Return Seen to Date on SmarTrend Arrowhead Pharma Call (ARWR)
March 07, 2019
from Comtex SmarTrend® News Briefs
Cramer's lightning round: Don't sell Disney yet—you'll want to own it long term
February 15, 2019
category Chipotle Mexican Grill Inc/ , Cenovus Energy Inc , Activision Blizzard Inc , and 17 more.
from CNBC.com News
Here's Why Arrowhead Pharmaceuticals Gained 38.2% in February
March 11, 2019
category JNJ , ARWR , Market News
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2019 The Pilot News | 214 N. Michigan | Plymouth, IN 46563 | (574) 936-3101 • 800-933-0356
All property rights for the entire contents of this publication shall be the property of The Pilot News.
No part hereof may be reproduced without prior written consent.
Privacy and Terms of Use


Site Design, Programming & Development by Surf New Media